A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

NCT07418879 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
RET Fusion
Pralsetinib

Interventions

DRUG: Pralsetinib
DRUG: Leucogen

Sponsor

Fudan University